Usmani, S., Kumar, S., Mateos, M., Ye, J. C., Atrash, S., Magen, H., Quach, H., Chu, M., Trudel, S., Richter, J., Rodriguez-Otero, P., Chuah, H., Gatt, M., Medvedova, E., Raza, S., Yoon, D. H., Ishida, T., Matous, J., Dachs, L. R., Onodera, K., Maffucci, C., Scott, E., Heuck, C., Zhang, J., Henninger, T., O'Rourke, L., Thakkar, P., Festa, M., Huang, L., Zhou, J., Takamoto, M., Pei, L., Lu, J., Au, N., Krevvata, M., Cohen, Y. (2025). Efficacy and safety of talquetamab + teclistamab in patients with Relapsed/Refractory multiple myeloma and extramedullary disease: Updated Phase 2 results from the redirectt-1 study with extended follow-up. Blood. https://doi.org/10.1182/blood-2025-698